CTRI/2020/06/025977CompletedPhase 2
A Randomized and Comparative Study to assess Safety and Efficacy of Supplemental Treatment of a herbal formulation - Aayudh Advance comprising essential oils in patients with Corona Virus 2019 (Covid-19)
Ms Shukla Ashar Impex Pvt Ltd0 sites120 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 120
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Subject willing to sign informed consent.
- •Subject age group of 18 years and above of both gender.
- •All patients with COVID-19 PCR positive (within 7 days/high clinical suspicion admitted to Corona Virus study participating hospital will be eligible.
- •Patients who are having mild to moderate symptoms of Covid-19 disease and tested positive for Covid-19 test.
Exclusion Criteria
- •Patients younger than 18 years.
- •Women who are pregnant or who intend to become pregnant for the next three months after taking the drug.
- •Patients allergic to type medications or any of the ingredient of the formulation.
- •Patients with a neurological history (seizures, epilepsy, etc.).
- •Patients with a previous history of psychiatric illnesses (depression, anxiety, suicide attempt).
- •Patients with cardiac pathologies or relevant chronic diseases that in the judgment of the clinician recommend the non-inclusion of the patient in the study.
- •Patients who would require artificial ventilation or oxygen supply.
- •Very severe patients of Covid 19.
- •Patients with severe hypertension, diabetes shall be excluded.
Investigators
Similar Trials
Completed
Phase 2
To study the Effectiveness of herbal formulation - Aayudh Advance as a supplementary treatment for the Corona Virus 2019 (Covid-19) infected patientsCTRI/2020/05/025161Ms Shukla Ashar Impex Pvt Ltd74
Recruiting
Phase 2
A clinical Trial on Oligospermia to evaluate the Siddha interventioCTRI/2022/09/046073Central Council for Research in Siddha Ministry of AYUSH
Active, not recruiting
Phase 1
Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson's with motor fluctuations.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028035Term: Movement disorderSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2018-002233-37-ITImpax Laboratories, LLC510
Active, not recruiting
Phase 1
Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028035Term: Movement disorderSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2018-002233-37-DEImpax Laboratories, LLC510
Active, not recruiting
Phase 1
Evaluate the safety and efficacy of IPX203 carbidopa-levodopa extended release capsules compared to carbidopa-levodopa immediate release tablets in patients with Parkinson’s with motor fluctuations.MedDRA version: 20.0Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: SOCClassification code 10029205Term: Nervous system disordersSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028035Term: Movement disorderSystem Organ Class: 10029205 - Nervous system disordersParkinson's diseaseEUCTR2018-002233-37-GBImpax Laboratories, LLC510